article Open AccessTop 1% cited

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

New England Journal of Medicine · 1996 · Vol. 335(14) · pp. 1001–1009

Frank M. Sacks✉(Brigham and Women's Hospital)Marc A. Pfeffer(Harvard University)Lemuel A. Moyé(The University of Texas Health Science Center at Houston)Jean L. Rouleau(Université de Sherbrooke)John D. Rutherford(The University of Texas Southwestern Medical Center)Thomas Cole(Washington University in St. Louis)Lisa Brown(Brigham and Women's Hospital)J. Wayne WarnicaJ. Malcolm O. Arnold(Victoria Hospital)Chuan‐Chuan Wun(The University of Texas Health Science Center at Houston)Barry R. Davis(The University of Texas Health Science Center at Houston)Eugene Braunwald(Brigham and Women's Hospital)

View via DOI Full-text PDF

Abstract

These results demonstrate that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels.

Lipoproteins and Cardiovascular Health Cardiac Valve Diseases and Treatments Acute Myocardial Infarction ResearchPravastatinMedicineMyocardial infarctionPlaceboInternal medicineCardiologyConfidence intervalCholesterolClinical endpointRandomized controlled trial

MeSH terms

AdultAgedAnticholesteremic AgentsCoronary Artery BypassCholesterolCoronary DiseaseDouble-Blind MethodFemaleHumansCholesterol, LDLMaleMiddle AgedMyocardial InfarctionRecurrenceAngioplasty, Balloon, Coronary

Citations

7,478

FWCI

369.00

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary